DUBLIN–(BUSINESS WIRE)–The “Hospital
Acquired Pneumonia (HAP) – Pipeline Review, H1 2019” drug
pipelines has been added to ResearchAndMarkets.com’s
offering.
This latest Pharmaceutical and Healthcare disease pipeline guide
Hospital Acquired Pneumonia (HAP) – Pipeline Review, H1 2019, provides
an overview of the Hospital Acquired Pneumonia (HAP) (Infectious
Disease) pipeline landscape.
Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired
during hospital stay. Symptoms include cough, fever, shaking chills,
confusion, headache and loss of appetite. Risk factors include chronic
lung disease, cigarette smoking, dementia, stroke, brain injury, heart
disease, liver cirrhosis and diabetes mellitus. Treatment includes
antibiotics and healthy lifestyle.
This latest pipeline guide provides comprehensive information on the
therapeutics under development for Hospital Acquired Pneumonia (HAP)
(Infectious Disease), complete with analysis by stage of development,
drug target, mechanism of action (MoA), route of administration (RoA)
and molecule type. The guide covers the descriptive pharmacological
action of the therapeutics, its complete research and development
history and latest news and press releases.
The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline
guide also reviews of key players involved in therapeutic development
for Hospital Acquired Pneumonia (HAP) and features dormant and
discontinued projects. The guide covers therapeutics under Development
by Companies /Universities /Institutes, the molecules developed by
Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and
Unknown stages are 8, 5, 10, 10, 2 and 1 respectively.
Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide
helps in identifying and tracking emerging players in the market and
their portfolios, enhances decision making capabilities and helps to
create effective counter strategies to gain competitive advantage. The
guide is built using data and information sourced from the researcher’s
proprietary databases, company/university websites, clinical trial
registries, conferences, SEC filings, investor presentations and
featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic
tracking processes ensure that the most recent developments are captured
on a real time basis.
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease). -
The pipeline guide reviews pipeline therapeutics for Hospital Acquired
Pneumonia (HAP) (Infectious Disease) by companies and
universities/research institutes based on information derived from
company and industry-specific sources. -
The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and
undisclosed stages. -
The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing
and collaboration details, R&D brief, MoA & other developmental
activities. -
The pipeline guide reviews key companies involved in Hospital Acquired
Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all
their major and minor projects. -
The pipeline guide evaluates Hospital Acquired Pneumonia (HAP)
(Infectious Disease) therapeutics based on mechanism of action (MoA),
drug target, route of administration (RoA) and molecule type. -
The pipeline guide encapsulates all the dormant and discontinued
pipeline projects. -
The pipeline guide reviews latest news related to pipeline
therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease)
Reasons to buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies. -
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage. -
Find and recognize significant and varied types of therapeutics under
development for Hospital Acquired Pneumonia (HAP) (Infectious Disease). - Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies. -
Plan mergers and acquisitions meritoriously by identifying key players
and it’s most promising pipeline therapeutics. -
Formulate corrective measures for pipeline projects by understanding
Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth
and focus of Indication therapeutics. -
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope. -
Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Introduction
- Hospital Acquired Pneumonia (HAP) – Overview
- Hospital Acquired Pneumonia (HAP) – Therapeutics Development
- Hospital Acquired Pneumonia (HAP) – Therapeutics Assessment
-
Hospital Acquired Pneumonia (HAP) – Companies Involved in Therapeutics
Development - Hospital Acquired Pneumonia (HAP) – Drug Profiles
- Hospital Acquired Pneumonia (HAP) – Dormant Projects
- Hospital Acquired Pneumonia (HAP) – Discontinued Products
- Hospital Acquired Pneumonia (HAP) – Product Development Milestones
Companies Mentioned
- Aridis Pharmaceuticals Inc
- AstraZeneca Plc
- Centauri Therapeutics Ltd
- Cumberland Pharmaceuticals Inc
- CytaCoat AB
- Destiny Pharma Plc
- Dong-A Socio Holdings Co Ltd
- Evaxion Biotech ApS
- MedImmune LLC
- Meiji Seika Pharma Co Ltd
- Merck & Co Inc
- Motif Bio Plc
- Nabriva Therapeutics Plc
- Polyphor AG
- Sealife PHARMA GMBH
- Shionogi & Co Ltd
- Spero Therapeutics Inc
- Tetraphase Pharmaceuticals Inc
- Wockhardt Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/m7q93l
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Respiratory
Drugs, Infectious
Diseases Drugs